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Abstract
Tuberculosis remains a major global public health problem despite the modest
infectious disease control efforts. Timely and accurate diagnosis is pivotal to the
reduction in tuberculosis related morbidity and mortality. In addition, drug resis-
tant form of tuberculosis is a serious threat to the efforts at tuberculosis control and
eradication. Hence; there is the need for efficient methods ofMycobacterium tuber-
culosis infection diagnosis and treatment. There are major advances in the laboratory
diagnostic methods for detection of Mycobacterium tuberculosis which seeks to com-
plement or replace the existing conventional methods in a view to reduction in
under-diagnosis and improved infectious disease management. Chest computer
tomographies, Cephid GeneXpert, Line probe are some of theMycobacterium tuber-
culosis diagnostic advances while chest x-ray, sputum microscopy/culture represent
some of the conventional methods of evaluation of bothMycobacterium tuberculosis
infection and its multi-resistant strain. Intriguingly, the conventional tuberculosis
diagnostics though time consuming and inefficient, its use still predominates in
high disease burden settings. Meanwhile, the slow transition to use of advanced
tuberculosis diagnostic methods seems to have an economic undertone. The
seemingly lack of cutting edge advanced Mycobacterium tuberculosis diagnostics in
high disease burden countries is attributable to their suboptimal health financing
model and over reliance on the donor organizations thereby retarding progress in
tuberculosis eradication.
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1. Introduction
Tuberculosis is a chronic granulomatous bacterial infection with a global occur-
rence [1–3]. This preventable and curable infectious disease has afflicted man since
antiquity [4]. Many parts of the world especially the developing nations are still
witnessing a rise in the number of new tuberculosis cases with its attendant conse-
quences [3]. This rising prevalence trend ofMycobacterium tuberculosis infection is
without prejudice to the strides and efforts in infection control [3].
Estimates have it that every minute someone somewhere gets infected with
Mycobacterium tuberculosis making it a common globally transmitted disease [5, 6].
Epidemiologically, the World Health Organization (WHO) and other multinational
health organization have reported tuberculosis as a worldwide pandemic [3, 7].
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A recent report by WHO revealed a global tuberculosis incidence of 6.3 million for
2016 reflecting a rise from the preceding year [3]. In the same vein, sub Saharan
Africa has a substantial burden of tuberculosis related morbidity and mortality as
reported in the 2016 WHO global tuberculosis report [3].
The current epidemiological profile of tuberculosis in Sub-Saharan Africa seems
to have an established association of the disease with poverty and social deprivation
[3, 5, 8]. Similarly, the burden of tuberculosis remains an obstacle to socioeconomic
development with a staggering direct and indirect cost of health financing [3, 9, 10].
The relationship between tuberculosis and social deprivation in addition to the
adverse socioeconomic developmental effect of tuberculosis creates a vicious cycle
of disease, poverty and poor productivity among the most disadvantaged in the
society.
Mycobacterium tuberculosis is the causative organism of tuberculosis which was
discovered by Robert Koch [11]. This granuloma forming microorganism is well
adapted to live in a man and cause disease under favorable condition(s). In the same
token, Mycobacterium tuberculosis is ubiquitous and has some unique features in its
genetic makeup and cell wall constituents that not only distinct it from other
organisms but also confers it with the strength of survival under harsh and stressful
conditions [12, 13].
The Mycobacterium tuberculosis genome is composed of insertion sequences (IS)
and phages which serve as unique features for its identification and speciation [12].
The type of IS that is abundant inMycobacterium tuberculosis is IS6110 [12]. The
knowledge of Mycobacterium tuberculosis genome is used in assessment of rate of
transmission, identification of a regional circulating strain and detection of trans-
border spread of the disease.
The main stay ofMycobacterium tuberculosis diagnosis has been the sputum
microscopy (Ziehl Neelsen) and the solid media culture (Lowestein-Jensen medium)
[14]. Although, these conventional methods ofMycobacterium tuberculosis identifica-
tion and isolation are still in use, newer methods of tuberculosis diagnostics which
include AmpiclorM. tuberculosis PCR test and Cephid GeneXpert is fast gaining
relevance and acceptance [15, 16]. The merits of use of molecular and immunological
techniques cannot be overemphasized in view of its additional benefit of infectious
organism speciation, isolate antimicrobial sensitivity and detection of specific muta-
tions that confer drug resistance (i.e., rpoB and KatG mutation) [15, 16]. The acqui-
sition and deployment of molecular tuberculosis diagnostics in priority high disease
burden areas would eventually increase rate ofMycobacterium tuberculosis infection
identification. This is predicated on the fact that early detection and treatment of
smear positive tuberculosis is attributed to improved cure rate [15].
2. Aim and objectives
This chapter is an exploratory study of existing tuberculosis diagnostics aimed at
highlighting the conventional and advanced methods ofMycobacterium tuberculosis
evaluation. The objective is to identify suitable and efficient method(s) of tubercu-
losis detection by way of profiling their merits and demerits.
3. Methods
This chapter is a descriptive research on the evolutionary trend of tuberculosis
diagnosis. Available literature would be used to identify existing methods ofMyco-
bacterium tuberculosis detection. A comparative analysis between the merits and
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demerits of old conventional and advanced molecular/immunological methods
would be carried out to ascertain what best serve the purpose of prompt and
efficient detection of Mycobacterium tuberculosis infection.
4. Literature review
4.1 Global burden of tuberculosis
Mycobacterium tuberculosis infection remains a significant public health chal-
lenge despite the modest achievements in its control at the global, regional and
country levels [3]. The alarming global prevalence rate ofMycobacterium tuberculosis
infection has been put at one-third of the world population [1, 3]. Sub-Saharan
Africa, South East Asia, and West Pacific region is home to most of the 22 countries
highly burdened by tuberculosis, and this ranking seldom change [3, 17].
World Health Organization reported that 6.3 million cases of tuberculosis were
notified in 2016 which might be under-estimation owing to the non-health seeking
behavior and poor documentation in some regions [3]. This tuberculosis epidemio-
logical pattern calls for sustained surveillance and prompt treatment to improve the
disease related morbidity and mortality [3].
The rising number of drug-resistant form of tuberculosis poses an additional
challenge on the inadequate resources allocated to healthcare delivery. In the year
2015, over 100 countries reported extensively drug-resistant tuberculosis [2]. Esti-
mates by the WHO revealed that 490,000 individual developed multidrug-resistant
tuberculosis in the year 2016 and only a fraction received treatment [3]. The threat
of drug-resistant tuberculosis as affirmed by 2016 global report on tuberculosis may
possibly be a consequence of inappropriate anti-tuberculosis medication use [3].
This emerging menace of drug resistant tuberculosis if not properly managed could
retard the progress made in the fight against tuberculosis.
The global distribution of tuberculosis infection is in close association with
poverty, immunosuppression and social deprivation [3, 5, 8, 17]. Sub Saharan Africa
has the world highest tuberculosis incidence of 356 per 100,000 populations per
year [2, 3]. Similarly, the social and clinical determinants of tuberculosis which
include HIV infection, diabetes mellitus, under-nutrition, migration and smoking
have been reported to preferentially afflict the young adult population [3, 5]. Nev-
ertheless, tuberculosis infection generally has no age, gender, racial or regional bias.
Mycobacteria consist of different pathogenic and saprophytic mycobacteria
species that are isolated from humans and the general environment [18, 19]. The
two broad groups of mycobacteria which are tuberculous and non-tuberculous
mycobacteria share some features but are largely distinguishable by molecular
analysis and the utilization of some microbiological test which include niacin
reduction test, nitrate test, and urease test [18, 19]. Lack of identification of the
species of mycobacteria infection from the outset has a clinical, management and
prognostic implication. The importance of mycobacteria speciation lie in their dif-
fering epidemiology, response to anti-tuberculosis, course of disease and long term
consequences [18, 19].
4.2 Pulmonary and extra-pulmonary tuberculosis
Literally, tuberculosis could affect any organ system of the body and clinical
presentation depends on the site of involvement. The human host immune system
influences the clinical pattern of tuberculosis presentation. Tuberculosis is generally
described as pulmonary if it involves the lungs and extra-pulmonary when there is
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involvement of other body parts excluding the lungs [8, 20]. This disease has also
been described as latent tuberculosis and active/open tuberculosis.
The initialMycobacterium tuberculosis infection could be dormant and symptom-
less (latent tuberculosis) or it could be symptomatic (progressive primary tubercu-
losis) manifesting commonly as miliary tuberculosis, primary tuberculous
pneumonia, and tuberculous meningitis [21].
Research has shown that 95% of primary Mycobacterium tuberculosis infection is
contained and represented as Ghon focus on the chest radiograph [21, 22]. Post-
primary tuberculosis is the most frequent mode of presentation of pulmonary
Mycobacterium tuberculosis infection [21, 22]. This form of tuberculosis could result
from an endogenous reactivation of the dormant bacilli from the primary infection
or a reinfection withMycobacterium tuberculosis.
Clinical manifestations of tuberculosis are body site-specific but may be sub-
clinical thereby posing a diagnostic challenge with frequent missed clinical cases.
Commonly, patients with tuberculosis have constitutional symptoms in addition to
body site specific symptom(s) [8, 23–25]. The diagnostic challenge of tuberculosis is
frequently observed among children and the elderly probably due to their unique
immune constitution and the nature of their airway defense mechanism [22, 25, 26].
Clinical manifestation of pulmonary tuberculosis serves as a prototype of Myco-
bacterium tuberculosis infection with specific and non-specific clinical presentations.
Cough is the predominant symptom of pulmonary tuberculosis [23–25]. Chronic
cough lasting for at least 2 weeks has been used as a flag off symptom for initiating
tuberculosis evaluation among individuals at the community level [3]. Difficulty in
breathing, chest pain, and chest deformity could be addition complaints by the
patients with pulmonary tuberculosis [23–25].
The physical examination equally poses an additional diagnostic challenge as
clinical findings could be non-specific and unhelpful in diagnosis. Pulmonary tuber-
culosis patients usually have respiratory system specific clinical signs of disease or
complication that include crepitation, bronchial breath sound, amphoric adventitious
sound and pleural rub [23–25]. Noteworthy is the clinical manifestation of extensive
lung destruction by way of fibrosis and contraction of lung volume [27].
4.3 Tuberculosis detection methods
4.3.1 Sputum microscopy/culture
The goal of investigation is to make a speedy, definite and accurate diagnosis of
Mycobacterium tuberculosis infection and to identify complication(s) of the disease.
The advances in tuberculosis investigation have provided increased sensitivity and
have assisted in improving transit time to diagnosis [28, 29].
Sputum microscopy (Ziehl Neelsen) is a common method for microbiological
profiling ofMycobacterium tuberculosis infection, especially in resource-limited
countries [14, 28]. The fluorescence microscopy forMycobacterium tuberculosis
though not readily available is an alternative to sputum microscopy (Ziehl Neelsen)
[30]. Both investigations use dye for staining but additionally, the fluorescence
microscopy requires the light-emitting diodes (LED) to visualize Mycobacterium
tuberculosis in sputum sample.
Although, sputum microscopy is cheap and can be rapidly performed, it is
operator dependent and its cost-effectiveness is marred by a decreased sensitivity in
pauci-bacillary states [15]. This diagnostic limitation has made extra-pulmonary
tuberculosis difficult to diagnose. The rate of false-positive results and inter-
operator differences in reportage of sputum microscopy has also compelled the
need to recognize molecular based investigation (Cephid GeneXpert) as the first
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line investigation for tuberculosis [15, 31]. Sputum microscopy is likely to continu-
ously be a cornerstone investigation in the evaluation of tuberculosis patient in the
resource constraint nations going by its cost-effectiveness. Hence, the need to
improve its operational capacity by way of research and development.
Sputum culture forMycobacterium tuberculosis represents an improvement well
and above microscopy, making it a definitive investigation of choice for the isola-
tion and identification of the infective organism [28–30]. Sputum culture has a
better sensitivity and specificity when compared with sputum microscopy [15, 31].
In view of this superiority, clinicians are advised to obtain culture confirmation of
tuberculosis where feasible.
Mycobacteria solid culture media which is typified by Lowenstein, Stonebrink,
or Ogawa medium is the predominant and sometimes the only form of culture used
in evaluation of tuberculosis [15, 32]. This mycobacteria culture is cheap, limits
contamination but slow taking about 4–8 weeks to detection of culture growth. The
merits of mycobacteria solid media culture is beclouded by the long transition to
diagnosis which is inimical to tuberculosis control because it delays commencement
of treatment. In contrast, liquid media which is represented by Bacteria Mycobac-
terial Growth Indicator Tube 960 and MB/Bact Alert 10 3D is more sensitive, faster
in detection of growth and the gold standard for mycobacteria isolation [15]. The
study by Munyati et al., estimated cost of mycobacteria liquid culture (1–3 culture)
to be in the range of $53–$163 [32]. By this estimated cost it is considered to be
impracticable to recommend mycobacteria liquid media culture in resource
limited setting despite its cost-effectiveness inMycobacterium tuberculosis infection
detection and isolation. The cost of procurement and maintenance of mycobacteria
liquid media culture may have informed the reason for its low availability and
utilization.
4.3.2 Radiologic study
Radiographic profiling for tuberculosis is an indispensable investigation in the
evaluation of infected patients. This investigative modality had a remarkable evo-
lution from the use of the x-rays to the use of advanced imaging modalities which
include the computer tomographic scan thereby upping the radiographic sensitivity
and specificity [25, 30].
A normal x-ray does not rule out tuberculosis, and no radiological finding is a
sine qua non for tuberculosis. This reality poses a diagnostic challenge for health
care providers especially in the evaluation of tuberculosis among the immune-
compromised. The x-ray imaging findings are predominantly abnormal in pulmo-
nary tuberculosis among the immune-competent [30, 33]. The upper zone and
apical lobe of the lower zone of the lungs are areas of predilection in pulmonary
tuberculosis [30]. In pulmonary tuberculosis, the commonest x-ray manifestation is
parenchyma involvement which is depicted by linear opacities, cavitations and
military shadows [15]. Pleural effusion, pleural thickening, lymphadenopathy, and
tuberculoma are the other extra-pulmonary manifestations that could be evident on
the chest radiographic examination.
Following chronic inflammation fromMycobacterium tuberculosis infection,
healing leaves behind nodules and parenchymal scarring. This is the radiologist
nightmare and a diagnostic challenge because residual x-ray findings represent a
stable disease but does not rule out active tuberculosis. In addition, atypical findings
on radiographs of immune-compromised individuals may lead to misdiagnosis of
Mycobacterium tuberculosis infection.
Chest computer tomography (CT) provides a diagnostic advantage in detecting
fine and equivocal lesions among tuberculosis patients when compared with x-ray
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films [15]. The findings on chest CT which could represent an active disease or
disease complications include features suggestive of consolidation, fibrosis, cavita-
tions and honey combing [15]. Similarly, the chest CT provides a clearer view of
extra-pulmonary involvement of Mycobacterium tuberculosis infection. For example
a “tree in bud” appearance on chest CT sufficiently represents active disease which
may not be discernible on x-ray films [15]. Despite, the added advantage of chest
CT over chest x-ray, microbiological test forMycobacterium tuberculosis is essential
for a definitive diagnosis.
4.3.3 Molecular methods
Tuberculin skin test for the latent tuberculosis is an ancient molecular investi-
gation that still reserves a place in clinical practice [30]. A major drawback of
tuberculin skin test is its inability to differentiate the latent tuberculosis from an
active disease. This diagnostic drawback has a therapeutic and prognostic implica-
tion. Line probe assay and Cephid GeneXpert System are the other advanced
molecular investigations that have enabled detection of drug resistant tuberculosis
[30]. Cephid GeneXpert System has been recommended as the first choice tuber-
culosis investigation especially among suspected cases of multidrug resistant disease
[34, 35]. This decision may have been predicated on the suitability of Cephid
GeneXpert System for use in resource limited environment due to its adequate
sensitivity, specificity and the minimal technical knowhow for its operation
[34, 35]. However, this guideline should be cautiously recommended for developing
nations because they may not cope with its financial implication.
Lipoarabinomannan (LAM) assay in urine has been commercially available for
over 20 years but its deployment for use in tuberculosis diagnostics is slow [36].
This molecular investigation is a point-of-care assay that enables detection of LAM
which is a mycobacterial cell wall glycolipid antigen [36, 37]. Lipoarabinomannan
assay in urine has enabled diagnosis of disseminated tuberculosis especially in
pauci-bacillary state and among HIV patients. A meta-analytic study has reported a
sub-optimal sensitivity for LAM assay in urine [38]. However, subsequent
improvement in LAM assay in urine by way of development of strip test version of
this molecular investigation improved its sensitivity, specificity and cost-
effectiveness.
4.3.4 Immunological methods
Immunological investigations for active tuberculosis include nucleic acid ampli-
fication tests and bacteriophage-based tests. These immunological investigations
have allowed detection of nucleic acid sequence ofMycobacterium tuberculosis and
assisted in genetic finger typing [28–30]. In furtherance, immunological methods of
Mycobacterium tuberculosis diagnosis provide an opportunity for the infective
organism speciation (MicroSeq 500 system, AccuProbe assay) and drug sensitivity
test [30]. Worthy of mention in the deployment of immunological investigation for
multidrug resistance evaluation are assessment of the rpoB gene mutation for
rifampicin resistance, the inhA gene and the katG gene mutation for low and high
level isoniazid resistance, respectively [30, 39].
In contrast to smear microscopy/culture, nucleic acid amplification test has a
greater positive predictive value (>95%), increase specificity and ability for rapid
confirmation of infection [15]. Nevertheless, the smear microscopy/culture still has
relevance in modern clinical practice because of its high sensitivity and utility when
drug sensitivity test of second line anti-tuberculosis is required [15].
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5. Conclusion
In conclusion, there is need to complement and replace where necessary the
conventional tuberculosis diagnostics with advanced cutting-edge microbiological,
imaging, molecular and immunologic investigations for prompt and adequate diag-
nosis. The diagnostic and therapeutic advantages of advanced methods of
mycobacteria detection call for its speedy deployment to priority areas to enhance
accuracy and efficiency of clinical evaluation. The cost of procurement and main-
tenance of this advanced methods of tuberculosis diagnosis maybe beyond the reach
of the health care systems of nations with high burden by tuberculosis. Hence, the
reason why donor funding is crucial in provision and maintenance of advanced
molecular and immunological tuberculosis diagnostics in high disease burden areas
especially in sub-Saharan Africa [40, 41].
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